奥西默替尼
医学
肺癌
内科学
肿瘤科
新辅助治疗
癌症研究
癌症
表皮生长因子受体
乳腺癌
埃罗替尼
作者
Jianxing He,Masahiro Tsuboi,Walter Weder,Ke‐Neng Chen,Maximilian J. Hochmair,Jin‐Yuan Shih,Sung Yong Lee,Kang‐Yun Lee,Nguyen Viet Nhung,Somcharoen Saeteng,Lunxu Liu,Ligang Xing,Nguyen Hoang Gia,Shuji Murakami,Yong Han,María Paz Saavedra,Seong Hoon Yoon,Carlos Henrique Andrade Teixeira,Carles Escriu,Alex Martínez‐Martí
摘要
Neoadjuvant osimertinib with or without chemotherapy demonstrated statistically significant improvement in the MPR rate over chemotherapy alone in patients with resectable, EGFR-mutated, stage II-IIIB NSCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI